-
Dec 4, 2024 | 
nature.com | Sarah Flossdorf |Sandra Sauer |Hartmut Goldschmidt |Monika Engelhardt |Robert Zeiser |Vladan Vucinic | +5 more
AbstractIdentifying patients who may benefit from autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma is crucial, especially in the era of effective induction and consolidation strategies. We analyzed data from 12763 patients enrolled in the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST), distinguishing those who underwent single (n = 8736) or tandem ASCT (n = 4027) from 1998 to 2021.
-
Jul 31, 2024 | 
onclive.com | Uwe Platzbecker
CommentaryVideoJuly 31, 2024Author(s):Uwe Platzbecker, MD, discusses efficacy data with the combination of all-trans retinoic acid and arsenic trioxide in high-risk acute promyelocytic leukemia.
-
Jan 6, 2024 | 
nature.com | Anne Sophie Kubasch |Song Wang |Sebastian Schwind |Klaus H. Metzeler |Madlen Jentzsch |Kristin Reiche | +2 more
AbstractB-cell maturation antigen (BCMA)-targeting chimeric antigen receptor (CAR) T cells revolutionized the treatment of relapsed/refractory multiple myeloma (RRMM). However, data on cellular (CAR) T cell dynamics and the association with response, resistance or the occurrence of cytokine release syndrome (CRS) are limited.
-
Dec 14, 2023 | 
sciencedirect.com | Uwe Platzbecker |Amer M Zeidan
There are more references available in the full text version of this article.
-
Oct 25, 2023 | 
nature.com | Klaus H. Metzeler |Georg-Nikolaus Franke |Vladan Vucinic |Uwe Platzbecker
To the Editor:Some of the gene mutations detected during the development of myeloid neoplasm are also frequently found in elderly individuals without diagnosed hematologic malignancy and here referred to as clonal hematopoiesis (CH) of indeterminate potential (CHIP) [1]. CHIP associates with an elevated risk of developing a myeloid neoplasm [1], as compared to non-CHIP conductors [1].
-
Oct 19, 2023 | 
onclive.com | Uwe Platzbecker |Rami D. Komrokji |Valeria Santini
Unmet Needs and Future of Lower-Risk MDSThe panel concludes their discussion with a look toward the future of lower-risk myelodysplastic syndrome treatment and the unmet needs that should be addressed.
-
Oct 12, 2023 | 
onclive.com | Uwe Platzbecker |Rami D. Komrokji |Valeria Santini
Rami Komrokji, MD, provides clinical insights on treatment decision-making, sequencing, and combinations for patients with myelodysplastic syndrome. Please note: Since the filming of this program, luspatercept has been approved by the FDA for the treatment of lower-risk MDS in the first-line setting.
-
Oct 12, 2023 | 
onclive.com | Uwe Platzbecker |Rami D. Komrokji |Valeria Santini
Matching-Adjusted Analysis Shows Acalabrutinib/Obinutuzumab Offers PFS Benefit Vs Zanubrutinib in CLL/SLL Without 17p DeletionsDr Brander on Findings From the TRANSCEND CLL 004 Trial in Relapsed/Refractory CLL/SLLDr Coombs on Switching to Treatment With a BCL-2 Inhibitor Vs a Covalent BTK Inhibitor in CLL/SLLAcalabrutinib Is Associated With Low Frequency of Cardiac Events Across 3 Randomized Trials in CLL
-
Oct 6, 2023 | 
onclive.com | Uwe Platzbecker
Uwe Platzbecker, MD, director, Medical I, University Hospital Leipzig, discusses key findings from the phase 3 COMMANDS trial (NCT03682536) with luspatercept-aamt (Reblozyl) in patients with lower-risk myelodysplastic syndrome (MDS) with anemia, as well as the clinical implications of FDA approval of luspatercept for patients in this population.
-
Oct 5, 2023 | 
onclive.com | Uwe Platzbecker |Rami D. Komrokji |Valeria Santini
Clinical Implications of Recent Data on New Agents in Lower-Risk MDSExpert perspectives on the clinical implications of recent clinical trial data on new therapies in lower-risk myelodysplastic syndrome.
